Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules

Journal of Immunology

Volumn 156, Issue 10, 1996, Pages 3821-3827

  Baskar, Sivasubramanian ^a   Clements, Virginia K ^a   Glimcher, Laurie H ^b   Nabavi, Nasrin ^c   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CYTOPLASM; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION, PASSIVE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED A; NEOPLASM TRANSPLANTATION; SARCOMA, EXPERIMENTAL; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0029869072     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chen, L. P , S. Ashe, W. Brady, I. Hellstrom, K. Hellstrom, J. Ledbetter, P. McGowan, and P. Linsley. 1992 Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
2. + T cells by B7-transfected melanoma cells. Science 259.368.
3. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L Nadler, G. Freeman, and L. Glimcher. 1993 Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
4. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med 181 619.
5. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
6. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell Curr. Opin. Immunol 6.722
7. Ostrand-Rosenberg, S , A. Thakur, and V Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes J. Immunol. 144.4068.
8. Ostrand-Rosenberg, S., C Roby, and V Clements. 1991 Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol 147:2419
9. Chen, C., A. Gault, L. Shen, and N. Nabavi 1994. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. J. Immunol. 4929.
10. Nabavi, N , A. Ghogawala, A. Myer, I. Griffith, W. Wade, Z. Chen, D. McKean, and L. Glimcher. 1989. Antigen presentation abrogated in cells expressing truncated Ia molecules. J. Immunol 142:1444.
11. Nabavi, N , G Freeman, A. Gault, D. Godfrey, L Nadler, and L Glimcher. 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360.266.
12. Chen, C., D. Faherty, A. Gault, S Connaughton, G. Powers, D. Godfrey, and N. Nabavi. 1994. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J. Immunol. 152:2105.
13. Oi, V., P. Jones, J. Goding, L. Herzenberg, and L. Herzenberg 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr. Top. Microbiol. Immunol 81:115.
14. + thymocytes. Nature 330:170.
15. Wilde, D., P. Marrack, J. Kappler, D. Dialynis, and F. Fitch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity, monoclonal antibody GK1.5 blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines J Immunol 131:2178.
16. Sarmiento, M., A Glasebrook, and F. Fitch 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T celil mediated cytolysis in the absence of complement. J. Immunol. 125:2665.
17. Coffman, R., and I. Weissman. 1981 B220: a B cell-specific member of the T200 glycoprotein family. Nature 289.681.
18. Sanchez-Madrid, F., P. Simon, S. Thompson, and T Springer. 1983. Mapping of antigenic and functional epitopes on the alpha and beta subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J. Exp. Med. 158:586.
19. Yang, G., K. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity ellicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules J Immunol. 154:2794.
20. June, C , J. Bluestone, L. Nadler, and C. Thompson. 1994. The B7 and CD28 receptor families. Immunol Today 15:321.
21. Azuma, M., D. Ito, H. Yagita, K. Okumura, J Phillips, L Lanier, and C. Somoza 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
22. Hathcock, K., G. Laszlo, H. Dickler, J. Bradshaw, P. Linsley, and R. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905.
23. Freeman, G., F. Borriello, R. Hodes, H. Reiser, K. Hathcock, G. Laszlo, A. McKnight, J. Kim, L. Du, D. Lombard, G. Gray, L. Nadler, and A. Sharpe. 1993 Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
24. Lenschow, D., G. Su, L. Zuckerman, N. Nabavi, C. Jellis, G. Gray, J. Miller, and J. Bluestone. 1993 Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl Acad. Sci. USA 90:11054.
25. Razi-Wolf, Z., F. Galvin, G. Gray, and H. Reiser. 1993. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc Natl. Acad. Sci. USA 90:11182.
26. Wu, Y., Y. Guo, and Y. Liu. 1993. A major costimulatory molecule on antigen-presenting cells, CTLA4 Ligand A, is distinct from B7. J. Exp Med. 178:1789.
27. h2 developmental pathways: application to autoimmune disease therapy Cell 80:707.
28. Katz, J., C. Benoist, and D. Mathis. 1995. T helper cell subsets in insulin-dependent diabetes. Science 268:1185.
29. Thompson, C. 1995. Distinct roles for the cosumulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979.
30. Colombo, M., and G. Forni. 1994. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15:48.
31. Ramarathinam, L , M. Castle, Y. Wu, and Y. Liu 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
32. Wu, T., A. Huang, E. Jaffee, H. Levitsky, and D. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415